Augmentation of NK cell therapy in ovarian cancer through mRNA-mediated cytokine expression.
Ovarian cancer is the most lethal malignancy in women and novel treatment modalities are urgently needed. Intraperitoneal infusion of natural killer (NK) cells is being explored as a cell-based immunotherapy. However, currently optimal stimulation of activity is hampered by the limited availability of cytokines. In this project, we therefore aim to provide co-stimulatory cytokines through transient expression achieved by intraperitoneal delivery of mRNA nanomedicines and assess the impact of this expression on tumor cell clearance in mouse models of ovarian cancer.

This project is funded by the Dutch Cancer Foundation and is a joint activity of the Departments of Biochemistry, Laboratory Hematology and Gynaecology of the Radboud University Medical Center in collaboration with one of the world-leading providers.

We are searching for a highly motivated candidate with experience in gene delivery and detection of expression, fluorescence microscopy and animal experimentation using tumor models. We offer a cutting-edge research project at the interface of nanomedicine and immunotherapy and a highly stimulating, interdisciplinary research environment with state-of-the-art research facilities.

Starting date as soon as possible and before 01 May 2019. The contract will first be limited to 6 months with extention to 15 months upon first demonstration of feasibility.

Upon commencement of employment we require a certificate of conduct (Verklaring Omtrent het Gedrag, VOG) and there will be, depending on the type of job, a screening based on the provided cv. Radboud university medical center's HR Department will apply for this certificate on your behalf.

Read more about the Radboudumc employment conditions and what our International Office can do for you when moving to the Netherlands.

Radboudumc

The Department of Biochemistry is one of the preclinical departments of the Radboudumc with research in targeted drug delivery, regenerative medicine and tissue engineering, and mitochondrial dynamics and metabolism. Fundamental research is conducted in close collaboration with clinical groups to promote a translation of fundamental insights into potential clinical applications. The current project builds on projects using protein engineering of DARPins to target cancer and intracellular delivery of proteins inhibiting intracellular signaling pathways.

Radboudumc
Radboudumc strives to be a leading developer of sustainable, innovative and affordable healthcare to improve the health and wellbeing of people and society in the Netherlands and beyond. This is the core of our mission: To have a significant impact on healthcare. To get a better picture of what this entails, check out our strategy film.

Read more about what it means to work at Radboudumc and how you can do your part.